The association between genetically proxied GLP-1 receptor agonists and cancer risks
Fei Zhou, Zhao Yang, Maoying Xing, Geng Zong, Chengwu Feng, Jing Wang, Xin Geng · 2026
Read The association between genetically proxied GLP-1 receptor agonists and cancer risks by Fei Zhou, Zhao Yang, Maoying Xing, Geng Zong, Chengwu Feng, Jing Wang, Xin Geng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13354389.txt.
Description
Fei Zhou and co-authors use genetics in 2026 to probe cancer risks tied to GLP-1 receptor agonist drugs. The diabetes and obesity drugs carry disputed long-term cancer signals in observational data. Gene variants near the GLP1R gene stood in for drug exposure in a Mendelian randomisation design, with summary data for 21 cancer types from public genome consortia.
Proxied drug use linked to lower breast and prostate cancer risk but higher head and neck plus thyroid cancer risk. Body mass explained about 3 percent of the endometrial cancer effect, while blood sugar explained small shares for two other cancers. United Kingdom Biobank checks matched the directions without reaching significance. Cancer-specific monitoring is advised.
Catalog record
| CREATOR | Fei Zhou, Zhao Yang, Maoying Xing, Geng Zong, Chengwu Feng, Jing Wang, Xin Geng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26134 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |